D. E. Shaw & Co. Inc. Trims Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

D. E. Shaw & Co. Inc. decreased its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 23.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 583,203 shares of the company's stock after selling 174,528 shares during the quarter. D. E. Shaw & Co. Inc. owned 1.08% of Fulcrum Therapeutics worth $2,741,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of FULC. BNP Paribas Financial Markets acquired a new position in Fulcrum Therapeutics during the fourth quarter worth about $38,000. Mariner LLC acquired a new position in Fulcrum Therapeutics during the fourth quarter worth about $78,000. Cantor Fitzgerald L. P. acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $94,000. Zacks Investment Management acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $99,000. Finally, Intech Investment Management LLC increased its stake in shares of Fulcrum Therapeutics by 74.9% in the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after buying an additional 13,057 shares during the period. Institutional investors and hedge funds own 89.83% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Leerink Partnrs raised Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Friday. Cantor Fitzgerald raised Fulcrum Therapeutics from a "neutral" rating to an "overweight" rating and set a $10.00 price objective for the company in a research note on Thursday, May 15th. Leerink Partners raised Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $4.00 to $12.00 in a research note on Friday. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $5.83.

Fulcrum Therapeutics Trading Up 5.2%

FULC stock traded up $0.32 during trading on Friday, hitting $6.44. The company had a trading volume of 898,658 shares, compared to its average volume of 972,394. The business has a 50-day moving average of $4.03 and a 200-day moving average of $3.91. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $10.13. The stock has a market cap of $347.62 million, a PE ratio of -20.77 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. Research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.